Is IEX a Buy? What to Consider in 2026
Last updated July 2026
Short answer
The bull case for IDEX Corporation (IEX) rests on Health & Science Technologies momentum: The Health & Science Technologies segment has been the standout, with organic revenue up roughly 11% and record orders in Q1 2026, led by life science, analytical instruments, and semiconductor-related fluidics. Revenue (TTM) is ~$3.4B. If you believe that thesis holds, the real questions become position sizing and overlap, not timing. The main risk to that view: IDEX is exposed to broad industrial cyclicality, and softness in chemical and certain short-cycle end markets has periodically offset strength elsewhere. Whether IEX is a buy comes down to whether you believe the thesis. This is informational, not a recommendation, and Walnut is not an investment adviser.
IDEX Corporation is an applied solutions company that designs and manufactures highly engineered pumps, flow meters, valves, fluidic systems, and other components used to move and measure fluids. It operates across three reporting segments: Health & Science Technologies (precision fluidics, optics, and sealing for life science, analytical instruments, and semiconductors), Fluid & Metering Technologies (industrial pumps, metering, and water and wastewater equipment), and Fire & Safety/Diversified Products (rescue tools, fire suppression components, and dispensing equipment). Its products are typically small pieces of larger customer systems where reliability matters more than price, which supports pricing power and recurring aftermarket demand. The investment picture is a classic serial-compounder story. IDEX generates strong margins and free cash flow from a broad portfolio of niche, market-leading product lines, and it reinvests through a steady cadence of bolt-on acquisitions that expand its addressable markets. Q1 2026 net sales rose about 9% to roughly $887 million with record orders near $988 million and adjusted EBITDA margins around 26%, prompting raised full-year guidance. The trade-off is that this consistency is well recognized by the market, so the stock carries a premium industrial multiple that leaves less room for disappointment if end markets soften or acquisitions underperform.
What's the case for buying IEX?
1. Health & Science Technologies momentum
The Health & Science Technologies segment has been the standout, with organic revenue up roughly 11% and record orders in Q1 2026, led by life science, analytical instruments, and semiconductor-related fluidics. This segment carries attractive margins and ties IDEX to secular demand in diagnostics, biotech tooling, and precision manufacturing. Continued strength here shifts the mix toward higher-value, less cyclical products.
2. Disciplined bolt-on acquisitions
IDEX has long grown by acquiring niche, high-margin flow-control and fluidics businesses and folding them into its operating model. Acquisitions and favorable currency contributed to the roughly 9% Q1 2026 sales growth on top of about 5% organic growth. A strong balance sheet and consistent free cash flow give the company capacity to keep compounding through deals.
3. Water, municipal, and mining exposure
Within Fluid & Metering Technologies, demand in municipal water, wastewater, and mining has been a bright spot, reflecting infrastructure and resource investment cycles. These end markets provide steadier, project-driven demand that can offset softness elsewhere. They also align IDEX with long-run water infrastructure spending themes.
4. Margin resilience and cash generation
IDEX sustained adjusted EBITDA margins around 26% in Q1 2026 and lifted full-year guidance on the back of record orders. Its decentralized operating model and pricing power on mission-critical components support durable margins through cycles. Consistent free cash flow funds dividends and continued acquisitions.
What are the risks to IEX?
IDEX is exposed to broad industrial cyclicality, and softness in chemical and certain short-cycle end markets has periodically offset strength elsewhere. Its acquisition-driven model carries integration and capital-allocation risk, and paying too much for deals or misjudging end markets could dilute returns. The stock trades at a premium industrial multiple (trailing P/E in the low 30s), so any growth or margin disappointment could compress the valuation. Currency swings, supply chain costs, and demand tied to customer capital spending in life science and semiconductors add variability. A slowdown in global manufacturing or infrastructure investment would pressure organic growth.
How is IEX valued? (as of July 2026)
Snapshot for IEX as of July 2026, sourced from Yahoo Finance and may be delayed. Valuation figures move with price and earnings; verify the current numbers with your broker before deciding.
- Revenue (TTM): ~$3.4B
- Q1 2026 net sales: ~$887M (+9% YoY)
- Q1 2026 orders: ~$988M (record, +13%)
- Adjusted EBITDA margin: ~26%
- Market cap: ~$16.5B
- Trailing P/E: ~33x
As of July 2026 IEX traded around $224 with a market cap near $16.5 billion and a trailing P/E in the low 30s, a premium typical of high-quality, acquisitive industrials. The valuation reflects consistent margins, record orders, and raised guidance, but it also leaves limited cushion if end markets weaken. The dividend yield sits near 1.3%, with the company having raised its payout for more than 15 consecutive years.
How do you decide if IEX is a buy?
Rather than asking whether IEX is a buy in the abstract, it tends to help to answer four questions:
- Thesis: do you believe the case above, and is it still true today?
- Time horizon: a single stock can be volatile, so a longer horizon absorbs more of the swings.
- Position sizing: a thesis can be right and the sizing still wrong; decide how much of your portfolio one name should be.
- Overlap: check whether you already hold IEX indirectly through an index or sector ETF before adding more.
For the full picture, see the IEX stock guide (what the company does, the ETFs that hold it, similar stocks, and the themes it fits). In Walnut you can ask its AI about IEX against your real portfolio and see your actual exposure before deciding.
The bottom line on IEX
The bottom line: IDEX Corporation's story right now is Health & Science Technologies momentum, with revenue (ttm) at ~$3.4B. If you believe that narrative continues, the call is about sizing IEX sensibly and checking overlap with what you own; if you doubt it (the risk: iDEX is exposed to broad industrial cyclicality, and softness in chemical and certain short-cycle end markets has periodically offset strength elsewhere.), it is not for you. Decide from the thesis, not the ticker. Walnut is not an investment adviser.
Build a basket around IEX with Walnut
Use IDEX Corporation as one constituent in a thematic basket Walnut's AI helps you assemble. Describe a thesis you believe in, the AI proposes the holdings and weights, and you approve before any broker order.
FAQ
Is IEX a good stock to buy right now?
+
The case for IDEX Corporation right now is Health & Science Technologies momentum, with revenue (ttm) at ~$3.4B. If you believe that thesis holds, IEX is a way to own it and the real questions are sizing and overlap, not timing; the main risk to that view is iDEX is exposed to broad industrial cyclicality, and softness in chemical and certain short-cycle end markets has periodically offset strength elsewhere. So it comes down to whether you believe the thesis. Walnut is not an investment adviser and this is not a recommendation.
What does IDEX Corporation do?
+
IDEX Corporation is an applied solutions company that designs and manufactures highly engineered pumps, flow meters, valves, fluidic systems, and other components used to move and
What are the main risks of IEX?
+
IDEX is exposed to broad industrial cyclicality, and softness in chemical and certain short-cycle end markets has periodically offset strength elsewhere. Its acquisition-driven model carries integration and capital-allocation risk, and paying too much for deals or misjudging end markets could dilute returns. The stock trades at a premium industrial multiple (trailing P/E in the low 30s), so any growth or margin disappointment could compress the valuation. Currency swings, supply chain costs, and demand tied to customer capital spending in life science and semiconductors add variability. A slowdown in global manufacturing or infrastructure investment would pressure organic growth.
What does IDEX Corporation do?
+
IDEX designs and manufactures highly engineered pumps, flow meters, valves, fluidic systems, and related components used to move and measure fluids. Its products serve industrial, water, life science, semiconductor, and fire and safety markets, usually as small but critical parts of larger customer systems.
Is IEX the stock exchange or a company?
+
The ticker IEX on the NYSE is IDEX Corporation, an industrial manufacturer of fluidics and flow-control equipment. It is not the IEX stock exchange (the Investors Exchange), which is a separate trading venue and not the company behind this ticker.
What are IDEX's business segments?
+
IDEX reports three segments: Health & Science Technologies (precision fluidics, optics, and sealing), Fluid & Metering Technologies (industrial pumps, metering, and water equipment), and Fire & Safety/Diversified Products (rescue tools, fire suppression, and dispensing). Health & Science Technologies has recently been the fastest-growing segment.
How did IDEX perform in its latest quarter?
+
In Q1 2026 IDEX reported net sales of about $887 million, up roughly 9% year over year, with adjusted EPS of $2.00 and record orders near $988 million. Adjusted EBITDA margin was about 26%, and the company raised its full-year guidance.
Walnut is informational and is not an investment adviser. This page is educational and not a recommendation to buy or sell IEX; figures are approximate and dated, and your own situation, time horizon, and risk tolerance should drive any decision. Verify current data before investing.